FDA Advisers Consider Novavax COVID-19 Vaccine This Week

An FDA panel will consider Novavax's COVID two-dose, protein-based vaccine this week, looking at some reports of adverse reactions, including rare events of myocarditis and pericarditis.
WebMD Health News

source https://www.medscape.com/viewarticle/975076?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?